[Alveolar hemorrhage as a possible adverse drug reaction by gefitinib (ZD1839, Iressa)].
We experienced a case in which severe alveolar hemorrhage occurred in the course of gefitinib therapy. A 56-year-old man with non-small cell lung cancer had been treated with CDDP + CPT-11, CDDP + GEM + VNR, CDDP + TXT. After the chemotherapy with these regimens was found to be ineffective, daily oral gefitinib was started. Four weeks later, the patient complained of cough, bloody sputum and dyspnea. Chest X-ray and CT showed bilateral infiltrations with air bronchogram. Fiberoptic bronchoscopy revealed alveolar hemorrhage with an increase of lymphocytes in the BALF. After the cessation of gefitinib therapy and the administration of steroid, he gradually recovered.
Ieki
Ryuji
R
Dept. of Respiratory Diseases, Tokyo Metropolitan Komagome Hospital.
Saitoh
Erika
E
Hashimoto
Emi
E
Ohta
Tomohiro
T
Yuasa
Kazumi
K
Iguchi
Mari
M
Okamura
Tatsuru
T
Shibuya
Masahiko
M
Moriyama
Sachiko
S
Goto
Hajime
H
D000230:Adenocarcinoma / Q000188:drug therapy*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D000077156:Gefitinib; D006470:Hemorrhage / Q000209:etiology*; D006801:Humans; D008171:Lung Diseases / Q000209:etiology*; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011650:Pulmonary Alveoli; D011799:Quinazolines / Q000009:adverse effects*; D012131:Respiratory Insufficiency / Q000209:etiology
D000970:Antineoplastic Agents; D011799:Quinazolines; D000077156:Gefitinib